December 22, 2015
Celgene Corp. has agreed to allow an India-based drugmaker to sell a generic version of its blood cancer treatment in the U.S. more than a year before the last-to-expire patent covering the drug runs out, as part of a settlement the companies reached Tuesday.
October 13, 2010
Celgene Corp. has slapped India's Natco Pharma Ltd. with a patent infringement lawsuit in an effort to keep a generic version of its top-selling drug Revlimid off the market.